Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFV890 and MAS825 in coronary heart disease patients with CHIP
2023-506741-34-00Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2024
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of DFV890 and MAS825 in atherosclerotic disease, myocardial infarction (MI) and clonal haematopoiesis of indeterminate potential (CHIP) (4 arms), sponsored by Novartis. Primary endpoints: Serum IL-6 level after DFV890, Serum IL-18 level after DFV890 and 1 more. Started Feb 2024; status: completed.
02
Drugs
DFV890MAS825
03
Conditions
atherosclerotic diseasemyocardial infarction (MI)clonal haematopoiesis of indeterminate potential (CHIP)
Beyond the preview
Go deeper on 2023-506741-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506741-34-00.